Subtopic Deep Dive

MicroRNA Therapeutics in Oncology
Research Guide

What is MicroRNA Therapeutics in Oncology?

MicroRNA therapeutics in oncology uses miRNA mimics and antagomirs delivered via lipid nanoparticles or extracellular vesicles to suppress tumors and inhibit metastasis in preclinical models.

Researchers develop miRNA mimics to restore tumor suppressor functions and antagomirs to block oncogenic miRNAs, tested in PDX models for efficacy and toxicity. Delivery systems like LNPs and EVs enhance stability and targeting. Over 10 key papers since 2011 cover challenges and advances, with Winkle et al. (2021) cited 1488 times.

Curated Papers

Key Challenges

Why It Matters

miRNA therapeutics target oncogenic dysregulation in cancers like HCC and breast cancer, complementing small molecules; Nagy et al. (2018) validated miRNA prognostic signatures across datasets for HCC therapy prediction (1449 citations). Bertoli et al. (2015) showed miRNAs as tools for breast cancer diagnosis and therapy (806 citations). Kim and Croce (2023) reviewed miRNA clinical trials advancing cancer strategies (335 citations), enabling personalized RNA drugs in oncology pipelines.

Key Research Challenges

Delivery System Stability

miRNAs degrade rapidly in circulation, requiring LNPs or EVs for protection; Dasgupta and Chatterjee (2021) detailed advances in delivery but noted off-target risks (285 citations). Winkle et al. (2021) highlighted nuclease resistance as a barrier in therapeutics (1488 citations).

Off-Target Toxicity

miRNA mimics cause unintended gene silencing in non-tumor tissues; Chen et al. (2022) discussed ncRNA targeting to overcome resistance but emphasized toxicity in cancer models (389 citations). Vakhshiteh et al. (2019) showed MSC exosomes with dual pro- and anti-tumor effects (274 citations).

Clinical Translation Gaps

Preclinical PDX efficacy fails in trials due to heterogeneous tumors; Kim and Croce (2023) analyzed miRNA trial trends revealing low success rates (335 citations). Kumar et al. (2024) proposed EVs as therapy targets but noted validation needs (859 citations).

Essential Papers

Noncoding RNA therapeutics — challenges and potential solutions

Melanie Winkle, Sherien M. El‐Daly, Muller Fabbri et al. · 2021 · Nature Reviews Drug Discovery · 1.5K citations

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets

Ádám Nagy, András Lánczky, Otília Menyhárt et al. · 2018 · Scientific Reports · 1.4K citations

Abstract Multiple studies suggested using different miRNAs as biomarkers for prognosis of hepatocellular carcinoma (HCC). We aimed to assemble a miRNA expression database from independent datasets ...

Extracellular vesicles as tools and targets in therapy for diseases

Mudasir A. Kumar, Sadaf Khursheed Baba, Hana Q. Sadida et al. · 2024 · Signal Transduction and Targeted Therapy · 859 citations

Abstract Extracellular vesicles (EVs) are nano-sized, membranous structures secreted into the extracellular space. They exhibit diverse sizes, contents, and surface markers and are ubiquitously rel...

MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer

Gloria Bertoli, Claudia Cava, Isabella Castiglioni · 2015 · Theranostics · 806 citations

Dysregulation of microRNAs (miRNAs) is involved in the initiation and progression of several human cancers, including breast cancer (BC), as strong evidence has been found that miRNAs can act as on...

MicroRNA in cardiovascular biology and disease

Anna Wojciechowska, Agata Osiak, Katarzyna Kozar · 2017 · Advances in Clinical and Experimental Medicine · 420 citations

MicroRNAs (miRNAs) are members of a non-coding RNA family. They act as negative regulators of protein translation by affecting messenger RNA (mRNA) stability; they modulate numerous signaling pathw...

Targeting non-coding RNAs to overcome cancer therapy resistance

Baoqing Chen, Mihnea P. Dragomir, Yang Chen et al. · 2022 · Signal Transduction and Targeted Therapy · 389 citations

Abstract It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non-coding R...

MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease

Tai-You Ha · 2011 · Immune Network · 355 citations

The great discovery of microRNAs (miRNAs) has revolutionized current cell biology and medical science. miRNAs are small conserved non-coding RNA molecules that post-transcriptionally regulate gene ...

Reading Guide

Foundational Papers

Start with Ha (2011, 355 citations) for miRNA roles in cancer basics, then Mavrakis et al. (2011, 261 citations) on miRNA-tumor suppressor networks in T-ALL.

Recent Advances

Study Winkle et al. (2021, 1488 citations) for therapeutics challenges, Kim and Croce (2023, 335 citations) for trial trends, and Kumar et al. (2024, 859 citations) for EV advances.

Core Methods

miRNA mimics/antagomirs via LNPs/EVs; high-throughput screens (Leivonen et al., 2013); prognostic validation on datasets (Nagy et al., 2018).

How PapersFlow Helps You Research MicroRNA Therapeutics in Oncology

Discover & Search

Research Agent uses searchPapers and exaSearch to find miRNA delivery papers like Dasgupta and Chatterjee (2021), then citationGraph maps therapeutics clusters from Winkle et al. (2021) to recent trials.

Analyze & Verify

Analysis Agent applies readPaperContent on Nagy et al. (2018) for HCC miRNA signatures, verifyResponse with CoVe checks prognostic claims, and runPythonAnalysis re-runs expression validations via pandas on supplementary data; GRADE scores evidence strength for oncology biomarkers.

Synthesize & Write

Synthesis Agent detects gaps in LNP delivery from Chen et al. (2022), flags contradictions in EV roles per Kumar et al. (2024); Writing Agent uses latexEditText, latexSyncCitations for trial review drafts, and latexCompile for figures on miRNA networks.

Use Cases

"Analyze miRNA expression data from Nagy 2018 for HCC prognostic models using Python."

Research Agent → searchPapers(Nagy 2018) → Analysis Agent → readPaperContent + runPythonAnalysis(pandas on GEO datasets) → matplotlib survival plots and statistical p-values.

"Write a LaTeX review on miRNA antagomirs for breast cancer therapeutics citing Bertoli 2015."

Synthesis Agent → gap detection(Bertoli et al. 2015 gaps) → Writing Agent → latexEditText(intro) → latexSyncCitations(10 papers) → latexCompile(PDF with miRNA pathway figure).

"Find GitHub repos with code for miRNA delivery simulations from recent papers."

Research Agent → citationGraph(Dasgupta 2021) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(LNP simulation scripts) → exportCsv(models data).

Automated Workflows

Deep Research workflow scans 50+ miRNA oncology papers via searchPapers, structures therapeutics report with GRADE grading on Winkle et al. (2021). DeepScan applies 7-step CoVe to verify EV delivery claims from Kumar et al. (2024). Theorizer generates hypotheses on antagomir combinations from Bertoli et al. (2015) and Chen et al. (2022).

Try Doxa for MicroRNA Therapeutics in Oncology Research

Frequently Asked Questions

What defines microRNA therapeutics in oncology?

miRNA mimics restore suppressors and antagomirs inhibit oncogenes, delivered by LNPs or EVs for tumor suppression (Winkle et al., 2021).

What are key methods in miRNA oncology delivery?

LNPs encapsulate miRNAs for stability; EVs from MSCs serve as natural carriers with tumor-homing (Dasgupta and Chatterjee, 2021; Kumar et al., 2024).

What are pivotal papers on miRNA cancer therapeutics?

Winkle et al. (2021, 1488 citations) covers challenges; Kim and Croce (2023, 335 citations) reviews clinical trials; Bertoli et al. (2015, 806 citations) details breast cancer applications.